PCSK9 | MedChemExpress (MCE) Life Science Reagents

PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related

Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

9

Inclisiran sodium

9 Publications Verification

Cat. No.: HY-132591A

Purity: 98.10%

Synonyms: ALN-PCSsc sodium

Target:

Research Areas:

Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

PF-06446846 hydrochloride

7 Cited Publications

Cat. No.: HY-120088A

CAS No.: 1632250-50-0

Purity: 99.44%

Target:

Research Areas:

PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34 .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

PF-06446846

7 Cited Publications

Cat. No.: HY-120088

CAS No.: 1632250-49-7

Target:

Research Areas:

PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

SBC-115076

5 Cited Publications

Cat. No.: HY-12402

CAS No.: 489415-96-5

Purity: 99.28%

Target:

Research Areas:

NF-κB Ser/Thr Protease Toll-like Receptor (TLR)

SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Evolocumab

3 Cited Publications

Cat. No.: HY-P9930

CAS No.: 1256937-27-5

Synonyms: AMG 145

Target:

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Pinostrobin

3 Cited Publications

Cat. No.: HY-N2127

CAS No.: 480-37-5

Category:

Flavonoids Monophenols Flavonones Phenols Plants Other Families Extract Disease Research Fields Inflammation/Immunology

Target:

Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related

Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Laroprovstat

1 Cited Publications

Cat. No.: HY-148673

CAS No.: 2455427-91-3

Purity: 99.97%

Synonyms: AZD0780; PCSK9-IN-12

Target:

Research Areas:

PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1

Laroprovstat (AZD0780) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a K_d value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Bococizumab

1 Cited Publications

Cat. No.: HY-P99187

CAS No.: 1407495-02-6

Synonyms: PF-04950615; RN316

Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Alirocumab

1 Cited Publications

Cat. No.: HY-P9928

CAS No.: 1245916-14-6

Synonyms: REGN727; SAR 236553

Target:

Research Areas:

Cardiovascular Disease Inflammation/Immunology

Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[9] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Alirocumab (anti-PCSK9)

1 Cited Publications

Cat. No.: HY-P9928A

CAS No.: 1245916-14-6

Synonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[9] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

SBC-110736

1 Cited Publications

Cat. No.: HY-101832

CAS No.: 1629166-02-4

Purity: 99.55%

Target:

Research Areas:

SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

PCSK9-IN-11

1 Cited Publications

Cat. No.: HY-152223

CAS No.: 2882035-56-3

Purity: 99.66%

Target:

Research Areas: